Diagnostic tests that inform selection and efficacy of therapy go by a few different names, including theranostics and companion diagnostics, but whatever you call them, the market for these tests is expected to grow at a compound annual growth rate of 4.9 percent and non-small cell lung cancer (NSCLC) tests are expected to account for 55 percent of market value this year, according to a report published this month by GlobalData.

Advanced low-grade non-Hodgkin lymphoma typically leads to relapse and death in patients who undergo conventional chemo and radiation therapies, but the emergence of radioimmunotherapy (RIT) has provided an encouraging alternative. Now researchers are finding quantitative SPECT data about dose uptake can be used to predict survival after therapy, according to a study published May 19 in the Journal of Nuclear Medicine.

A simple blood test is being presented as a viable means of predicting a patient’s odds of developing neurodegenerative disease within two to three years. Preliminary research came out in March and will be elaborated in a late-breaking session July 28 at the 2014 annual meeting of the American Association for Clinical Chemistry (AACC).

A knowledgeable voice among nuclear medicine leaders, the president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) returns to the pages of Molecular Imaging Insight with some commentary on recent changes in the industry, new items on the molecular imaging agenda and worthy initiatives in the wings.

Tau has been identified as one of the keys to unlocking neurodegenerative disease, including Alzheimer’s. However, efforts to develop an ideal tau PET agent continue to be an uphill battle, according to a review published May 15 in the Journal of Nuclear Medicine.

A minimally invasive PET scan could tell clinicians about a patient’s exocrine function without all of the usual pains of conventional testing, according to a study published May 19 in the Journal of Nuclear Medicine.

In this video, BBC reporter Fergus Walsh is the first to undergo an MRI scan as part of the largest scan study to date and describes how the study is evolving.

IBA Molecular North America, Inc. (IBA Molecular) announced the signing of a 3-year group purchasing agreement with Premier, Inc. (Premier), a leading health care improvement company, to offer PET radiopharmaceuticals, including 18F-Fluorodeoxyglucose (FDG), a diagnostic radiotracer used in oncology, neurology and cardiology, to Premier member imaging centers across the country.